Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase: Relevance to hypoxia/reoxygenation injury

Cardiovascular Toxicology

Volumn 1, Issue 3, 2001, Pages 205-213

  Oliveira, Paulo J ^a   Rolo, Anabela P ^a   Palmeira, Carlos M ^a   Moreno, António J M ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Carvedilol; Mitochondria; Mitochondrial permeability transition pore; Oxidative stress model; Xanthine hypoxanthine

Indexed keywords

CALCIUM ION; CARVEDILOL; FREE RADICAL; HYPOXANTHINE; SUPEROXIDE; XANTHINE OXIDASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CARBAZOLE DERIVATIVE; CYCLOSPORIN; PROPANOLAMINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CELL DAMAGE; CONTROLLED STUDY; DRUG EFFECT; HEART MITOCHONDRION; HEART PROTECTION; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION SWELLING; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; ANIMAL; ANOXIA; CELL MEMBRANE POTENTIAL; METABOLISM; OXYGEN CONSUMPTION; PATHOLOGY; PHYSIOLOGY;

ANIMALIA;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANOXIA; CALCIUM; CARBAZOLES; CYCLOSPORINE; HYPOXANTHINE; MALE; MEMBRANE POTENTIALS; MITOCHONDRIA, HEART; MITOCHONDRIAL SWELLING; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PROPANOLAMINES; RATS; SUPEROXIDES; XANTHINE OXIDASE;

EID: 0035750084     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:1:3:205     Document Type: Article

References (31)

1. Ferrari, R. (1996). The role of mitochondria in ischemic heart disease. J. Cardiovasc. Pharmacol. 28(Suppl. 1): S1-S10.
2. Di Lisa, F., Menabò, R., Canton, M., and Petronilli, V. (1998). The role of mitochondria in the salvage and injury of the ischemic myocardium. Biochim. Biophys. Acta 1366: 69-78.
3. Baker, J.E., Felix, C.C., Olinger, G.N., and Kalyanaraman, B. (1988). Myocardial ischemia and reperfusion: direct evidence for free radical generation by electron spin resonance spectroscopy. Proc. Natl. Acad. Sci. USA 85:2786-2789.
4. Ward, A., McBurney, A., and Lunec, J. (1994). Evidence for the involvement of oxygen-derived free radicals in ischemia-reperfusion injury. Free Radic. Res. Commun. 20:21-28.
5. Ferrari, R., Agnoletti, L., Comini, L., Gala, G., Bachetti, T., Cargnoni, A., et al. (1998). Oxidative stress during myocardial ischemia and heart failure. Eur. Heart J. 19: B2-B11.
6. Giron-Calle, J., Zwizinski, C.W., and Schmid, H.H.O. (1994). Peroxidative damage to cardiac mitochondria -II. Immunological analysis of modified adenine nucleotide translocase. Arch. Biochem. Biophys. 315:1-7.
7. 2+-dependent pore of possible relevance to reperfusion-induced injury. Biochem. J. 266:33-39.
8. Halestrap, A.P., Kerr, P.M., Javadov, S., and Woodfield, K-Y. (1998). Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim. Biophys. Acta 1366:79-94.
9. Jurado, F., Bellon, J.M., Pareja, J.A., Golitsin, A., Millán, L., Pascual, G., et al. (1998). Effects of ischemia-reperfusion and cyclosporin-A on cardiac muscle ultrastructure. Histol. Histopathol. 13:761-774.
10. Hendrickson, S.C., St. Louis, J.D., Lowe, J.E., and Abdel-Aleem, S. (1997). Free fatty acid metabolism during myocardial ischemia and reperfusion. Mol. Cell Biochem. 166:85-94.
11. Maulik, N., Yoshida, T., and Das, D.K. (1999). Regulation of cardiomyocyte apoptosis in ischemic reperfused mouse heart by glutathione peroxidase. Mol. Cell. Biochem. 196:13-21.
12. Ruffolo, R.R. Jr., Boyle, D.A., Brooks, D.P., Feuerstein, G.Z., Venuti, R.P., Lukas, M.A., et al. (1992). Carvedilol, a novel cardiovascular drug with multiple actions. Cardiovasc. Drug Rev. 10:127-157.
13. Dunn, C.J., Lea, A.P., and Wagstaff, A.J. (1997). Carvedilol - a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 54: 161-185.
14. Yue, T-L., Cheng, H-Y., Lysko, P.G., McKenna, P.J., Feueustein, R., Gu, J-L., et al. (1992). Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263:92-98.
15. Yue, T-L., McKenna, P.J., Ruffolo, R.R. Jr., and Feuerstein, G. (1992). Carvedilol, a new b-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur. J. Pharmacol. 214:277-280.
16. Moreno, A.J.M., Santos, D.L., and Palmeira, C.M. (1998). Ischemic heart disease: the role of mitochondria - carvedilol prevents lipid peroxidation of mitochondrial membranes. Rev. Port. Cardiol. 17:II-63-II-77.
17. Oliveira, P.J., Santos, D.L., and Moreno, A.J.M. (2000). Carvedilol inhibits the exogenous NADH dehydrogenase in rat heart mitochondria. Arch. Biochem. Biophys. 374: 279-285.
18. •- release as a byproduct of respiration. Free Radical Res. Commun. 18:127-137.
19. 2+-dependent inner-membrane permeability transition. Biochem. J. 294:719-725.
20. Broekemeier, K.M., Dempsey, M.E., and Pfeiffer, D.R. (1989). Cyclosporin A is a potent inhibitor of the inner membrane mitochondrial transition in liver mitochondria. J. Biol. Chem. 264:7826-7830.
21. Kamo, N., Muratsugu, M., Hongoh, R., and Kobatake, Y. (1979). Membrane potential of mitochondria measured with an electrode sensitive to tetraphenyl phosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state. J. Membr. Biol. 49:105-121.
22. 2+ concentrations associated with glutamate excitotoxicity in cultured rat brain neurons. Neurosci. Lett. 162: 149-152.
23. Halliwell, B. (1975). The superoxide dismutase activity of iron complexes. FEBS Lett. 56:34-38.
24. Oliveira, P.J., Marques, M.P.M., Carvalho, L.A.E.B., and Moreno, A.J.M. (2000). Effects of carvedilol on isolated heart mitochondria: evidences for a protonophoretic mechanism, Biochem. Biophys. Res. Commun. 276:82-87.
25. Eddy, L.J., Stewart, J.R., Jones, H.P., Engerson, T.D., McCord, J.M., and Downey, J.M. (1987). Free radical-producing enzyme, xanthine oxidase, is undetectable in human hearts. Am. J. Physiol. 253:H709-H711.
26. Saksela, M., Lapatto, R., and Raivio, K. (1999). Irreversible conversion of xanthine dehydrogenase into xanthine oxidase by a mitochondrial protease. FEBS Lett. 443:117-120.
27. Oliveira, P.J., Coxito, P.M., Rolo, A.P., Santos, D.L., Palmeira, C.M., and Moreno, A.J.M. (2000). Inhibitory effect of carvedilol in the high-conductance state of the calcium-sensitive mitochondrial permeability transition pore, Eur. J. Pharmacol. 412 (3):231-237.
28. Zago, E.B., Castilho, R.F., and Vercesi, A.E. (2000). The redox state of endogenous pyridine nucleotides can determine both the degree of mitochondrial oxidative stress and the solute selectivity of the permeability transition pore. FEBS Lett. 478:29-33.
29. 2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidylprolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem. J. 268: 153-160.
30. Pruett, J.K., Walle, T., and Walle, U. (1980). Propranolol effects on membrane repolarization time in isolated canine Purkinje fibers: threshold tissue content and the influence of exposure time. J. Pharmacol. Exp. Ther. 215:539-543.
31. Neugebauer, G., Akpan, W., Mollendorff, E. V., Neupert, P., and Reif, K. (1987). Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Ther. 10(Suppl. 11): S85-S88.